JenaValve Technology
- Company typePrivate
- Founded2006
- HeadquartersIrvine, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
JenaValve Technology firmographics
Firmographics- Name
- JenaValve Technology
- Legal name
- JenaValve Technology, Inc.
- Website
- https://jenavalve.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
JenaValve Technology industry classification
Industry- Product category
- Transcatheter Heart Valve Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)
- akta.pro secondary industry
- Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)
Keywords
Where JenaValve Technology is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
JenaValve Technology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Trilogy Transcatheter Heart Valve System Sales: One-time hardware sales of the Trilogy transcatheter heart valve system to hospitals and cardiac centers for treatment of aortic regurgitation and aortic stenosis. Revenue generated from device sales as the company begins US commercialization in April 2026 following FDA approval.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
JenaValve Technology product offering
Product offeringCore offering
JenaValve Technology develops and manufactures the Trilogy Transcatheter Heart Valve (THV) System, a transcatheter aortic valve replacement (TAVR) platform designed to treat symptomatic, severe aortic regurgitation (AR) and aortic stenosis (AS) in patients at high surgical risk. The system comprises the Trilogy Valve (self-expanding nitinol frame with proprietary locator technology and porcine pericardial tissue), the Trilogy Delivery System (single-action deployment catheter), and the Trilogy Introducer Sheath System (85 cm hydrophilically-coated sheath). It is the first and only FDA-approved TAVR device for aortic regurgitation and the first transfemoral TAVR approved for both AR and AS in Europe.
Product overview
JenaValve Technology offers the Trilogy Transcatheter Heart Valve (THV) System, a comprehensive TAVR (Transcatheter Aortic Valve Replacement) solution designed for treating symptomatic, severe aortic regurgitation. The system comprises three integrated components: the Trilogy Valve (self-expanding nitinol frame with porcine pericardial tissue and proprietary locator technology), the Trilogy Delivery System (for precise catheter-based deployment), and the Trilogy Introducer Sheath System (85cm sheath extending to the sinotubular junction). The proprietary locator technology differentiates the system by enabling secure anchoring to native anatomy without requiring calcification, making it the first and only FDA-approved TAVR device for aortic regurgitation and the first TAVR system with true dual-disease treatment capability (AR and aortic stenosis) approved in Europe.
Differentiator
Problem solved
Functional benefit
Brands
- Trilogy System: The Trilogy Transcatheter Heart Valve System - a TAVR system FDA-approved for treatment of symptomatic severe aortic regurgitation in high surgical risk patients.
Products and services
- Trilogy Transcatheter Heart Valve (THV) System A transcatheter aortic valve replacement (TAVR) system designed for transfemoral delivery to treat symptomatic, severe aortic regurgitation. Features proprietary locator technology that clips onto native anatomy for secure anchoring without requiring calcification, enabling treatment of AR patients who cannot undergo open-heart surgery. Sold to hospitals and cardiac centers.
- Trilogy Delivery System Catheter-based delivery component engineered for stability, precision and reliability from access to deployment. Features catheter deflection to center the valve above the annulus, integrated rotation and axial positioning for commissural alignment, and a simple one-step deployment mechanism. Sold to hospitals as part of the Trilogy THV System.
- Trilogy Introducer Sheath System 85 cm pre-shaped, hydrophilically-coated introducer sheath that extends to the sinotubular junction, protecting the Trilogy Valve and patient through deployment. Sold to hospitals as part of the Trilogy THV System.
Quantifiable outcome
- 95.0% technical success rate (Pivotal + CAP, n=700) compared to 74-86% with off-label TAVR devices
- +6 more outcomes
Companies that use JenaValve Technology
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles1 record
JenaValve Technology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
JenaValve Technology partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered strategic and core.
- American Society of Echocardiography (ASE)strategicPartnership announced November 2023 to advance detection and diagnosis of aortic regurgitation. Collaboration with leading professional society in echocardiography to improve patient identification and care pathways.
- egnite, Inc.strategicStrategic partnership announced June 2023 to uncover trends in care for patients with aortic regurgitation. Leverages egnite's AI-driven database and industry-leading cardiovascular data to quantify prevalence and treatment patterns. First study presented at TVT Structural Heart Summit estimated over 500,000 US patients with moderate or severe AR.
- Peijia MedicalcoreLicense and development agreement signed December 2021 (announced January 2022). Peijia Medical granted exclusive license to develop, manufacture, and commercialize Trilogy System in greater China region. First commercial implants performed in Hong Kong in May 2023.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
JenaValve Technology competitors and assessment
Company assessmentDirect peers
- Edwards Lifesciences: Global TAVR market leader with the Sapien platform (transfemoral and transapical delivery). Most direct competitor in transcatheter aortic valve replacement; attempted acquisition of JenaValve blocked by FTC in 2026.
- Medtronic: Major TAVR competitor with the Evolut self-expanding platform. Competes head-to-head with JenaValve in transcatheter aortic valve replacement across both AR (off-label) and AS indications.
- Abbott: TAVR competitor with the Navitor (self-expanding) and Portico platforms. Directly comparable transcatheter aortic valve portfolio targeting overlapping patient populations and cardiac centers.
Emerging players
- Boston Scientific: Structural heart player with the ACURATE neo2 TAVR platform. Competes in the same transcatheter aortic valve space but with a smaller installed base than Edwards, Medtronic, or Abbott.
- 4C Medical Technologies: Structural heart startup developing transcatheter mitral and tricuspid valve therapies. Comparable early-stage structural heart medtech player with novel transcatheter valve technology, though focused on mitral rather than aortic disease.
- Ancora Heart: Structural heart company developing transcatheter mitral valve repair technology. Comparable early-stage transcatheter valve company targeting underserved valvular disease patient populations.
Regional players
- Peijia Medical: China-based structural heart company that is both an investor and exclusive distributor for JenaValve's Trilogy in greater China. Also develops its own TAVR technologies, creating a partner/competitor hybrid relationship.
- Venus Medtech: Chinese TAVR developer with approved transcatheter aortic valve products in greater China. Comparable structural heart franchise focused on the Chinese market with overlapping technology to Trilogy.
- MicroPort CardioFlow: Subsidiary of MicroPort Scientific developing the VitaFlow TAVR system. Comparable transcatheter aortic valve technology with focus on the Chinese market.
Broad incumbents
- CryoLife (Artivion): Cardiac and vascular surgery company with tissue heart valves and surgical valve repair products. Adjacent competitor in the structural heart space, focused more on surgical (open) rather than transcatheter valves.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
JenaValve Technology social profiles
Digital presenceJenaValve Technology compliance and trust
Trust signalCompliance3 records
JenaValve Technology financial estimates
Financial estimateRevenue estimate
Valuation estimate
JenaValve Technology leadership team
Management profileNumber of profiles
Profiles6 records
JenaValve Technology subsidiaries and ownership
Company hierarchySubsidiaries2 records
JenaValve Technology funding detail
Funding detailFunding overview
Funding rounds11 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
JenaValve Technology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about JenaValve Technology
What does JenaValve Technology do?
JenaValve Technology develops and manufactures the Trilogy Transcatheter Heart Valve (THV) System, a transcatheter aortic valve replacement (TAVR) platform designed to treat symptomatic, severe aortic regurgitation (AR) and aortic stenosis (AS) in patients at high surgical risk. The system comprises the Trilogy Valve (self-expanding nitinol frame with proprietary locator technology and porcine pericardial tissue), the Trilogy Delivery System (single-action deployment catheter), and the Trilogy Introducer Sheath System (85 cm hydrophilically-coated sheath). It is the first and only FDA-approved TAVR device for aortic regurgitation and the first transfemoral TAVR approved for both AR and AS in Europe.
Is JenaValve Technology a public or private company?
JenaValve Technology is a private company. It is classified as venture growth investor backed and is currently operating.
When was JenaValve Technology founded?
JenaValve Technology was founded in 2006. It employs 101 to 250 people.
Where is JenaValve Technology based?
JenaValve Technology is headquartered in Irvine, United States, in the North America region.
How does JenaValve Technology make money?
One revenue line is on record: trilogy Transcatheter Heart Valve System Sales.
Who are JenaValve Technology's main competitors?
Direct peers on record are Edwards Lifesciences, Medtronic and Abbott. Emerging players are Boston Scientific, 4C Medical Technologies and Ancora Heart. Regional players are Peijia Medical, Venus Medtech and MicroPort CardioFlow. CryoLife (Artivion) is listed as a broad incumbent.
Does JenaValve Technology have an API?
No public API is recorded for JenaValve Technology.
What industry is JenaValve Technology in?
JenaValve Technology's product category is Transcatheter Heart Valve Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHAFAK, Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems). Its NAICS code is 339112 and its SIC code is 3841.